We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal (GI) and liver diseases. Our most advanced program targets the farnesoid X receptor (FXR), which is central to modulating GI and liver diseases. We believe that potency, sustained exposure and continuous target engagement are key to optimizing therapeutic benefit with an FXR targeted therapy. Leveraging our extensive chemistry and biology expertise, we have built a proprietary library of over 2,500 FXR compounds and have selected MET642 to advance into a Phase 2 study in ulcerative colitis.

We will continue to discover and develop novel therapies targeting FXR as well as other drug targets, particularly those involved in inflammation and/or fibrosis. Based on our internal chemistry and biology expertise, we believe we can develop innovative treatments for a range of GI and liver diseases.